After the unexpected success of their PHOENYCS GO study for dapirolizumab pegol in lupus earlier this fall, Biogen and UCB ...
Long-term treatment with anifrolumab significantly reduced the rate of organ damage compared with SOC among patients with SLE ...
A phase 3 trial of Biogen (NASDAQ:BIIB) and UCB's (OTCPK:UCBJF)(OTCPK:UCBJY) dapirolizumab pegol for systemic lupus ...
The American College of Rheumatology (ACR) 2024 Convergence has just concluded, showcasing significant advancements and ...
In a new study, researchers discovered a potential new gene biomarker, ELF1, a protein coding gene, that can be used to ...
Natural treatments for lupus are typically used as complementary therapies alongside conventional treatments. Learn more ...
demonstrating significant clinical improvement in disease activity in people living with moderate-to-severe systemic lupus erythematosus, or SLE. The results were shared during an oral, late-breaker ...
Fate said it is also enrolling a second treatment arm under the Phase 1 Autoimmunity study to evaluate a single dose of FT819 ...
The 1.5 million Americans estimated to have the autoimmune disease lupus already have plenty to manage—what with the pain, ...
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback